US.AMGN · Amgen

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.8,
      "details": {
        "atrPct": 2.2495679464975717,
        "turnoverUsdM": 1590.999460288524,
        "liquidityPoints": 0.8,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.6,
    "stopLevels": {
      "symbol": "US.AMGN",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 359.1692,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 2,
        "macd_score": 3,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.6,
      "stop_loss_percent": 4.5,
      "take_profit_price": 402.7685,
      "target_multiplier": 2.2,
      "technical_strength": 2.15,
      "take_profit_percent": 7.1
    },
    "positionPoints": 1.8,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.5780808068176446,
    "stopLossPercent": 4.4991358929951435,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 81.7,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 64.7,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 17
  },
  "market": {
    "ma20": 365.9835,
    "ma50": 351.0186,
    "close": 376.09,
    "prevClose": 376.04,
    "avgVolume20": 2318663,
    "volumeRatio": 1.82,
    "changePercent": 0.01
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 17,
    "details": {
      "ret_5d": 0.032731926497736596,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 17,
      "vcp_bonus": 0,
      "vol_ratio": 1.8492122955334271,
      "ret_points": 8,
      "vol_points": 6,
      "range_ratio": 0.9133372632049181,
      "volat_points": 0,
      "day_range_pct": 0.020965753101286868,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 81.7,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 4.6,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 92,
        "contribution": 4.6
      },
      {
        "raw": 14,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 70,
        "contribution": 14
      },
      {
        "raw": 4.6,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 30.67,
        "contribution": 4.6
      },
      {
        "raw": 6,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 30,
        "contribution": 6
      },
      {
        "raw": 7.8,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 78,
        "contribution": 7.8
      },
      {
        "raw": 23.7,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 79,
        "contribution": 23.7
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "觀望",
    "result": 64.7,
    "details": [
      "基本面分析總分: 4.6/5分",
      "資金流分析總分: 14/20分",
      "市場環境分析總分: 4.6/15分",
      "催化劑分析: 6/20分",
      "風險管理總分: 7.8/10分",
      "技術信號分析總分: 23.7/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 6,
      "基本面": 4.6,
      "資金流": 14,
      "市場環境": 4.6,
      "情緒分析": 4,
      "技術信號": 23.7,
      "風險管理": 7.8
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 1
            }
          },
          "catalystPoints": 6
        }
      },
      "基本面": {
        "max": 5,
        "grade": "優秀",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0.75,
          "roePoints": 0.75,
          "debtPoints": 0.3,
          "marginPoints": 0.6,
          "turnoverUsdM": 1590.999460288524,
          "volumePoints": 0.5,
          "revenuePoints": 0.4,
          "dividendPoints": 0.4,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "良好",
        "items": {
          "cmfPoints": 1.6,
          "mfiPoints": 2.4,
          "obvPoints": 4,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.AMGN",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 710.4899991500001,
                "ma50": 717.6342017599999,
                "name": "QQQ",
                "close": 682.059998,
                "points": 0.4
              },
              "spy": {
                "ma20": 746.6545068500001,
                "ma50": 745.00220184,
                "name": "SPY",
                "close": 739.02002,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.2495679464975717,
          "atrPoints": 3,
          "cciPoints": 0.8,
          "vixPoints": 0,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 2,
              "sentimentScoreRaw": 0.6
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141033888,
                "url": "https://finnhub.io/api/news?id=dc9f1bf41e02bd122f2a1f9dd94d33948e396f55182f930a70ef93716b7257fb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.",
                "category": "company",
                "datetime": 1785157202,
                "headline": "Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know"
              },
              {
                "id": 141001695,
                "url": "https://finnhub.io/api/news?id=db558615651d5148d6e4a0a245b62e76d9ea605fec3d5a4ec78e8183a02178bc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Looking back on therapeutics stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Amgen (NASDAQ:AMGN) and its peers.",
                "category": "company",
                "datetime": 1784856751,
                "headline": "Therapeutics Stocks Q1 Teardown: Amgen (NASDAQ:AMGN) Vs The Rest"
              },
              {
                "id": 141000869,
                "url": "https://finnhub.io/api/news?id=efd506a525fe7cec52851172777a84cd46dea36062f19f96ffac5d2b17009731",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (AMGN) concluded the recent trading session at $371.47, signifying a +1.48% move from its prior day's close.",
                "category": "company",
                "datetime": 1784843404,
                "headline": "Amgen (AMGN) Rises As Market Takes a Dip: Key Facts"
              },
              {
                "id": 140992342,
                "url": "https://finnhub.io/api/news?id=ddb94091ec8d3c5554f22b0052de2a60cdd479dd78921ac7502ae52834a251c3",
                "image": "https://www.chartmill.com/images/uploads/CM_Breakout_Stocks_Small_free_bb09e243c7.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Amgen (AMGN) shows strong technical health with a 7/10 rating and a high-quality 9/10 setup pattern, signaling a potential breakout from consolidation near support.",
                "category": "company",
                "datetime": 1784806825,
                "headline": "Amgen Inc (NASDAQ:AMGN) Shows Technical Strength and Breakout Setup"
              },
              {
                "id": 140989308,
                "url": "https://finnhub.io/api/news?id=0b0e6dac5c1617eb42aa813615a3459f9196acbb7f8cb1677e299847b7c12338",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Earlier in July, a federal judge blocked Colorado’s plan to impose a 70% price cap on Amgen’s blockbuster arthritis drug Enbrel, halting a significant state-level pricing move. The ruling eased concerns that aggressive state pricing limits on Enbrel could spread more widely, reducing a key regulatory overhang for Amgen’s portfolio. We’ll now explore how this legal setback to Colorado’s price cap effort could influence Amgen’s investment narrative and perceived long-term risks. Find 47...",
                "category": "company",
                "datetime": 1784758253,
                "headline": "Colorado Enbrel Price Cap Setback Might Change The Case For Investing In Amgen (AMGN)"
              },
              {
                "id": 140979287,
                "url": "https://finnhub.io/api/news?id=bbfba8fce2d22100fcc7fa55170930f58a742563e75c8af5f83ce529d9f38625",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "A recent court decision blocking Colorado’s planned 70% price cap on Enbrel has removed a key regulatory overhang for Amgen (AMGN) and is refocusing attention on the stock’s earnings setup. See our latest analysis for Amgen. Beyond the court ruling, Amgen’s share price has quietly built positive momentum, with a 30 day share price return of 8.48% and year to date share price return of 11.78%, while the 1 year total shareholder return of 23.41% and 3 year total shareholder return of 70.66%...",
                "category": "company",
                "datetime": 1784694560,
                "headline": "Amgen (AMGN) Clears An Enbrel Overhang, Is The Stock Fully Priced?"
              },
              {
                "id": 140922733,
                "url": "https://finnhub.io/api/news?id=57316ac4de7d44a44d7551a1220cc88d465156b1c8dd591dd00ed4a3a28c1320",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
                "category": "company",
                "datetime": 1784218203,
                "headline": "Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?"
              },
              {
                "id": 140904283,
                "url": "https://finnhub.io/api/news?id=9febfa3e97d1f8a39dfd518043a89e00e344fbdbdef1391c6d7ba9ff3285985c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (AMGN) closed the most recent trading day at $355.25, moving 1.44% from the previous trading session.",
                "category": "company",
                "datetime": 1784065802,
                "headline": "Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know"
              }
            ],
            "raw_source": [
              {
                "id": 141035864,
                "url": "https://finnhub.io/api/news?id=cb78fd5b6d971beed68ff684ddaa78ca399ac0d5c1918fac5995e99449126988",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Let's have a look at the top dow jones gainers and losers one hour before the close of the markets of today's session.",
                "category": "company",
                "datetime": 1785179405,
                "headline": "Monday's session: top gainers and losers in the dow jones index"
              },
              {
                "id": 141036037,
                "url": "https://finnhub.io/api/news?id=2cc61cdbabe57465c6369f88d1cd57b760ec36da2bc51946d6d2f08f0584f756",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Here is a way to get paid a significant income stream today from Eli Lilly stock, which you keep no matter what, while setting a price far below current levels where you would be willing to buy.",
                "category": "company",
                "datetime": 1785177225,
                "headline": "Collect 9.8% On LLY Stock Now, Own It 30% Cheaper If It Dips"
              },
              {
                "id": 141034620,
                "url": "https://finnhub.io/api/news?id=c19dab74e14a1da00a0b26c3d0894666e72cf4b8ea237811786f25e0118168da",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Stay informed about the performance of the dow jones index in the middle of the day on Monday. Uncover the top gainers and losers in today's session for valuable insights.",
                "category": "company",
                "datetime": 1785170404,
                "headline": "Top dow jones movers in Monday's session"
              },
              {
                "id": 141033888,
                "url": "https://finnhub.io/api/news?id=dc9f1bf41e02bd122f2a1f9dd94d33948e396f55182f930a70ef93716b7257fb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.",
                "category": "company",
                "datetime": 1785157202,
                "headline": "Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know"
              },
              {
                "id": 141032185,
                "url": "https://finnhub.io/api/news?id=1d131c897db42ea543d59bae1c01b213e7d1915e0bbb0ee5d34da31eeea3e96a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Most biotech investors treat FBT and IBB as two names for the same trade, but the structural differences buried in their index methodologies have produced shockingly different outcomes depending on where the market's momentum actually lives.",
                "category": "company",
                "datetime": 1785151515,
                "headline": "FBT and IBB Are Not the Same Biotech Bet, and 5 Years of Returns Prove It"
              },
              {
                "id": 141033829,
                "url": "https://finnhub.io/api/news?id=f44986411b5d5c5246d9ff515ae37c06ae04189d71b1cbe690556f104ea78a28",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Most recently the leader of buzzy startup Tessera Therapeutics, Severino will look to improve the fortunes of a company facing emerging competition and declining sales for its prized gene therapy Elevidys.",
                "category": "company",
                "datetime": 1785147360,
                "headline": "Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO"
              },
              {
                "id": 141012380,
                "url": "https://finnhub.io/api/news?id=1049f08222cb659a27f732cbe315d0815331fce9aae8adcb12d874d1f0f61c7c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2262233592/image_2262233592.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "Regeneron Pharmaceuticals, Inc. buy case: Dupixent & Libtayo fuel growth despite volatility & Eylea biosimilar risks; margins to recover. Click for an REGN update.",
                "category": "company",
                "datetime": 1784924522,
                "headline": "Regeneron: I'm Not Concerned About The Declining ROIC And Operating Margins"
              },
              {
                "id": 141008873,
                "url": "https://finnhub.io/api/news?id=0a485f1fa08b431da2d3ffb0109a55c9e9c924b2f7213f2766d5efe23d30f2e8",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Wondering what's happening in today's session for the dow jones index? Stay informed with the top movers within the dow jones index on Friday.",
                "category": "company",
                "datetime": 1784920204,
                "headline": "Which dow jones stocks are moving on Friday?"
              },
              {
                "id": 141007648,
                "url": "https://finnhub.io/api/news?id=5bcda10be03a46b1fe216e890282d109e2647da983830ccd0a9f8c26dd627589",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The Dow Jones (^DJI) is packed with iconic businesses that have built strong brands and durable market positions. A select few continue to thrive, delivering solid returns and proving their resilience in an evolving market.",
                "category": "company",
                "datetime": 1784915108,
                "headline": "3 Dow Jones Stocks with Solid Fundamentals"
              },
              {
                "id": 141007833,
                "url": "https://finnhub.io/api/news?id=5cf7707e497795cff166871fea3644e4993aa459d5c66b0aef77e644708aaf19",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The decision to no longer seek approval of amlitelimab is the latest setback for a treatment once hailed as a future blockbuster. One analyst expects Sanofi to now pursue “strategic action” to boost its pipeline.",
                "category": "company",
                "datetime": 1784892900,
                "headline": "Sanofi halts development of troubled immune drug in eczema"
              },
              {
                "id": 141012034,
                "url": "https://finnhub.io/api/news?id=b5a42172189829410801627488e189929042c9aee461775a6f5bab01cf5149e6",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "https://www.amgen.com/newsroom/company-statements/amgen-statement-on-fda-data-submission-for-tavneos?_gl=1*p4mfe*_up*MQ..*_ga*MjAxMjQ2Mjc4My4xNzg0ODk1MTYx*_ga_CBMSV0J9VL*czE3ODQ4OTUxNjEkbzEkZzEkdDE3ODQ4OTUxODMkajM4JGwwJG",
                "category": "company",
                "datetime": 1784880867,
                "headline": "Amgen Disagrees With FDA Proposal To Withdraw TAVNEOS From U.S. Market; Submitted Data And Analyses To FDA To Request Hearing On TAVNEOS"
              },
              {
                "id": 141005737,
                "url": "https://finnhub.io/api/news?id=09b0ee23712127e790437bd7239e1db83cc0d6bbe776a957098f94fa4e6d192b",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/24/Closse-up-Shot-Of-White-Pills-On-Conveyo.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Trump sets a 2-year ultimatum for generic drugmakers to reshore U.S. production or face tariffs up to 200%.",
                "category": "company",
                "datetime": 1784874313,
                "headline": "Two Years to Build or Pay 200% — Which US Pharma Stocks Win?"
              },
              {
                "id": 141001695,
                "url": "https://finnhub.io/api/news?id=db558615651d5148d6e4a0a245b62e76d9ea605fec3d5a4ec78e8183a02178bc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Looking back on therapeutics stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Amgen (NASDAQ:AMGN) and its peers.",
                "category": "company",
                "datetime": 1784856751,
                "headline": "Therapeutics Stocks Q1 Teardown: Amgen (NASDAQ:AMGN) Vs The Rest"
              },
              {
                "id": 141000869,
                "url": "https://finnhub.io/api/news?id=efd506a525fe7cec52851172777a84cd46dea36062f19f96ffac5d2b17009731",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (AMGN) concluded the recent trading session at $371.47, signifying a +1.48% move from its prior day's close.",
                "category": "company",
                "datetime": 1784843404,
                "headline": "Amgen (AMGN) Rises As Market Takes a Dip: Key Facts"
              },
              {
                "id": 140997116,
                "url": "https://finnhub.io/api/news?id=bc6828dc888b16a18d4634c6b054cfddda83b8c9bd63e85c8a711b2f5a305ff4",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Stay informed about the performance of the dow jones index one hour before the close of the markets on Thursday. Uncover the top gainers and losers in today's session for valuable insights.",
                "category": "company",
                "datetime": 1784833803,
                "headline": "These dow jones stocks are moving in today's session"
              },
              {
                "id": 140995615,
                "url": "https://finnhub.io/api/news?id=2b1f0452b3a057ed6a9cc36b34e4ba342fc311f608df0b5acc4cf4ca752eee72",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Stay informed about the performance of the dow jones index in the middle of the day on Thursday. Uncover the top gainers and losers in today's session for valuable insights.",
                "category": "company",
                "datetime": 1784824804,
                "headline": "What's going on in today's session: dow jones movers"
              },
              {
                "id": 140998074,
                "url": "https://finnhub.io/api/news?id=3c44c743d1bcf2a3d934bc59f7bc8777ff1351e9911e6554c104a544377e0eb8",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/23/Woman-Touching-Stomach-Painful-Suffering.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Analyst initiates a Buy rating on Palisade Bio with an $8 target, highlighting PALI-2108's multi-billion dollar potential in IBD treatment.",
                "category": "company",
                "datetime": 1784815607,
                "headline": "Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2"
              },
              {
                "id": 140996248,
                "url": "https://finnhub.io/api/news?id=d79a92d059cad5703142a835ff2763e844d94c47b3c52e8a5be7f5bb39a5e428",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2285918278/image_2285918278.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "Zevra Therapeutics jumps on FDA Orange Book patent exclusivity to 2041; profitability, cash-rich balance sheet, celiprolol pipeline. Click for more on ZVRA stock.",
                "category": "company",
                "datetime": 1784815020,
                "headline": "Zevra Therapeutics: Worthy Of An Initial Holding"
              },
              {
                "id": 140993214,
                "url": "https://finnhub.io/api/news?id=e8df886607e7a4a48f8e5a5e691c2c2675b250e7843487a9c35b5aae584e5e0b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Getting kicked off the Dow Jones Industrial Average sounds like a death sentence for a stock, but a handful of booted dividend giants went on to reward patient shareholders with stunning gains and steady income streams that index investors missed out on entirely.",
                "category": "company",
                "datetime": 1784808811,
                "headline": "Verizon Was Booted From the Dow – 5 Dividend Giants Got the Same Treatment and Eventually Soared"
              },
              {
                "id": 140992342,
                "url": "https://finnhub.io/api/news?id=ddb94091ec8d3c5554f22b0052de2a60cdd479dd78921ac7502ae52834a251c3",
                "image": "https://www.chartmill.com/images/uploads/CM_Breakout_Stocks_Small_free_bb09e243c7.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Amgen (AMGN) shows strong technical health with a 7/10 rating and a high-quality 9/10 setup pattern, signaling a potential breakout from consolidation near support.",
                "category": "company",
                "datetime": 1784806825,
                "headline": "Amgen Inc (NASDAQ:AMGN) Shows Technical Strength and Breakout Setup"
              },
              {
                "id": 140989308,
                "url": "https://finnhub.io/api/news?id=0b0e6dac5c1617eb42aa813615a3459f9196acbb7f8cb1677e299847b7c12338",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Earlier in July, a federal judge blocked Colorado’s plan to impose a 70% price cap on Amgen’s blockbuster arthritis drug Enbrel, halting a significant state-level pricing move. The ruling eased concerns that aggressive state pricing limits on Enbrel could spread more widely, reducing a key regulatory overhang for Amgen’s portfolio. We’ll now explore how this legal setback to Colorado’s price cap effort could influence Amgen’s investment narrative and perceived long-term risks. Find 47...",
                "category": "company",
                "datetime": 1784758253,
                "headline": "Colorado Enbrel Price Cap Setback Might Change The Case For Investing In Amgen (AMGN)"
              },
              {
                "id": 140986548,
                "url": "https://finnhub.io/api/news?id=7cb79220ad70b189344fbbba8e43157b3a8f7c7e24e49c584714ad0fa25f6667",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Healthcare stocks declined late Wednesday afternoon, with the NYSE Healthcare Index down 0.4% and th",
                "category": "company",
                "datetime": 1784749691,
                "headline": "Sector Update: Healthcare Stocks Softer Late Afternoon"
              },
              {
                "id": 140981764,
                "url": "https://finnhub.io/api/news?id=fe4752d3fa507f1a71bb2fbc30af30104fbf8a525645ed5a3e73ad0ec80ed866",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "A pharmaceutical giant is on an incredible run fueled by blockbuster drugs, forcing investors to ask if the price of admission already accounts for the entire victory lap.",
                "category": "company",
                "datetime": 1784726247,
                "headline": "LLY Has Momentum. The Question Is The Price"
              },
              {
                "id": 140981682,
                "url": "https://finnhub.io/api/news?id=d73b8658c4448b35fd4a7380769b5eedbe275248128d315f8585dc7b2ee0b428",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "DIVO quietly hands retirees a monthly check from a portfolio of blue-chip giants, but a 150% payout ratio and a debt-laden pharma holding raise fair questions about what is actually backing that income.",
                "category": "company",
                "datetime": 1784725590,
                "headline": "How retirees are earning $0.18 monthly per share without options risk"
              },
              {
                "id": 140979287,
                "url": "https://finnhub.io/api/news?id=bbfba8fce2d22100fcc7fa55170930f58a742563e75c8af5f83ce529d9f38625",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "A recent court decision blocking Colorado’s planned 70% price cap on Enbrel has removed a key regulatory overhang for Amgen (AMGN) and is refocusing attention on the stock’s earnings setup. See our latest analysis for Amgen. Beyond the court ruling, Amgen’s share price has quietly built positive momentum, with a 30 day share price return of 8.48% and year to date share price return of 11.78%, while the 1 year total shareholder return of 23.41% and 3 year total shareholder return of 70.66%...",
                "category": "company",
                "datetime": 1784694560,
                "headline": "Amgen (AMGN) Clears An Enbrel Overhang, Is The Stock Fully Priced?"
              },
              {
                "id": 140983640,
                "url": "https://finnhub.io/api/news?id=be232ffd5f24c370e540bfb5a76468eb8bccb5950f42060db323284f869a8881",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/22/Washington-D-c---Usa---February-4--2025-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Trump says imported generic drugs face 0% tariffs for 2 years, before 100% and then 200% duties.",
                "category": "company",
                "datetime": 1784671990,
                "headline": "Trump Sets August 1 Start for Generic Drug Tariff Clock, Warns of 200% Duties: Companies Must 'Build Plant and Equipment' in US"
              },
              {
                "id": 140976349,
                "url": "https://finnhub.io/api/news?id=82d9525d03dbe9eedcd561c6aff3946e429bd9bd996312bd1f19747ca485afce",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Management lifted its profit outlook, and investors have more than quadrupled that bet. The question now is what they're really paying for.",
                "category": "company",
                "datetime": 1784664282,
                "headline": "Eli Lilly Stock And The Price Of Confidence"
              },
              {
                "id": 140977296,
                "url": "https://finnhub.io/api/news?id=2156e62ea72fb87c2e8a66d842546b25bdca4dfd005c093a2de9b2ce83bb4ec8",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 1.3% on an annualized basis producing an average annual return of 13.64%. Currently, Amgen has a market capitalization of $197.77 billion.",
                "category": "company",
                "datetime": 1784653232,
                "headline": "$100 Invested In Amgen 15 Years Ago Would Be Worth This Much Today"
              },
              {
                "id": 140965383,
                "url": "https://finnhub.io/api/news?id=252d2af92d35c827be0d28207193e18bcbf3b37d6beb9fe055e4471376919788",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/20/Merck.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "For the tens of millions of Americans who cannot push their LDL cholesterol (trivially known as "bad cholesterol") low enough on statins alone, the strongest backup has meant needles. That changed on July 16,",
                "category": "company",
                "datetime": 1784567501,
                "headline": "Merck Just Won The Race For The First Cholesterol Pill: What It Means For Your Heart And Your Portfolio"
              },
              {
                "id": 140963496,
                "url": "https://finnhub.io/api/news?id=bc608928391c0c27da5cadd9ac50f9928a454c0a3aea9f08ae87c36fb245460a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen is set to report Q2 earnings next month, with analysts expecting a single digit EPS decline.",
                "category": "company",
                "datetime": 1784550953,
                "headline": "Amgen Earnings Preview: What to Expect"
              },
              {
                "id": 140959510,
                "url": "https://finnhub.io/api/news?id=a9c2ac51c5f6093a7eef3814a52242e894c9058def09703ffad12d8ef3fb6476",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as  Merck  Keytruda, the best-selling drug in the world.  Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form of bispecific antibodies.  Bispecific antibodies are being tested by  Bristol Myers Squibb  (with its partner  BioNTech  ),  AstraZeneca  and the biotech firm  Summit Therapeutics  ADCs have already rung up big sales for Astra,  Pfizer Gilead Sciences  and  Roche Holding  but Merck has a strong contender in development.",
                "category": "company",
                "datetime": 1784549820,
                "headline": "Merck’s Keytruda Faces a Patent Cliff. These New Cancer Drugs Could Take Over."
              },
              {
                "id": 140957651,
                "url": "https://finnhub.io/api/news?id=b48119d669b046cb291e67f2f812348161794131c0b00f6b915027443a57822d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as  Merck  Keytruda, the best-selling drug in the world.  Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form of bispecific antibodies.  Bispecific antibodies are being tested by  Bristol Myers Squibb  (with its partner  BioNTech  ),  AstraZeneca  and the biotech firm  Summit Therapeutics  ADCs have already rung up big sales for Astra,  Pfizer Gilead Sciences  and  Roche Holding  but Merck has a strong contender in development.",
                "category": "company",
                "datetime": 1784527200,
                "headline": "What Comes After Merck’s Keytruda? The Race for the Next Standard Cancer Treatment."
              },
              {
                "id": 140955778,
                "url": "https://finnhub.io/api/news?id=989fbbfabc0bbae37e46ab4bb57fb1e7723b8234cb8ccda6eb5366a42f05e17e",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2285994413/image_2285994413.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "Xencor (XNCR) stays a Strong Buy as XmAb819 and XmAb942 advance; key data due 2026–2027 and $542M cash extends runway—read the outlook now.",
                "category": "company",
                "datetime": 1784493770,
                "headline": "Xencor: Strong Buy, XmAb819 Presentation, And End Of 2026 XmAb942 Interim Data"
              },
              {
                "id": 140936339,
                "url": "https://finnhub.io/api/news?id=470eed78aef521d1505aefe2aede17ebbadb13c0593ab30619763ecd9da322b0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Stock Market Today: The Dow Jones index drops Friday as oil prices rise. Nasdaq dives as Netflix stock sinks on soft guidance.",
                "category": "company",
                "datetime": 1784315394,
                "headline": "Stock Market Today: Dow, Nasdaq Slide As Oil Climbs, Netflix Tumbles; Eli Lilly In Buy Zone (Live Coverage)"
              },
              {
                "id": 140932834,
                "url": "https://finnhub.io/api/news?id=78e5e8f079a9163c9983b838a804c3a1454e950919ff3b711da86ab6186281b7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The FDA just approved the first once-daily oral PCSK9 pill, and five major stocks now sit in the crosshairs. Not all of them come out ahead, and the biggest surprise winner may not be the company that makes the drug.",
                "category": "company",
                "datetime": 1784300733,
                "headline": "The First Oral Cholesterol Pill Is Here. Which of These 5 Stocks Benefits Most?"
              },
              {
                "id": 140931584,
                "url": "https://finnhub.io/api/news?id=1e557962fcb764201bb68ee9362993d37da30fb96f982a1598a9e060492ef4c3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "DIVO has raised its monthly payout three years running and sits on $5.25 billion in assets, but one holding carries a debt load that raises questions about how long the streak can continue.",
                "category": "company",
                "datetime": 1784295977,
                "headline": "The $5.25 billion ETF paying dividends that grew three years straight right now"
              },
              {
                "id": 140931537,
                "url": "https://finnhub.io/api/news?id=6670b5cafef5a7f113453de06d340e6165f15e1b8162e3ee2125b35f101cba1a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Management is promising structural growth without shipping more drives, and the market is buying it. But the real test of that high-tech promise is around the corner.",
                "category": "company",
                "datetime": 1784293799,
                "headline": "Seagate Stock And The Bet On A Denser Future"
              },
              {
                "id": 140931668,
                "url": "https://finnhub.io/api/news?id=a75e28199e3d20bac597def1d5aca238f003cb7327962cda5c3588cf11690307",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Zenas BioPharma (ZBIO) remains undervalued, as investor concerns over its phase 3 INDIGO trial for o",
                "category": "company",
                "datetime": 1784290436,
                "headline": "Zenas BioPharma Bear Case Overlooks Obexelimab's Commercial Potential, Wedbush Says"
              },
              {
                "id": 140931559,
                "url": "https://finnhub.io/api/news?id=ea1920539c088131ba2462cebb1c9ce3ea0e914773b4698b74ee66b70f528ee0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Management laid out a bigger vision for the business, and investors have more than agreed. The question now is how much of that future is already in the price.",
                "category": "company",
                "datetime": 1784289735,
                "headline": "Fortinet Stock Is Pricing In A Much Bigger Future"
              },
              {
                "id": 140930770,
                "url": "https://finnhub.io/api/news?id=a9cb5ef50d046f2090172e80e8d04609cceed9932ff390ad50fd6714924f060a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The weight-loss boom has created one of the market's biggest opportunities — and some of its most punishing failures.",
                "category": "company",
                "datetime": 1784284758,
                "headline": "The weight-loss drugs boom is creating both winners and wipeouts: One Big Investment Idea"
              },
              {
                "id": 140923898,
                "url": "https://finnhub.io/api/news?id=0599a730d1c9c8a1c033764e0e99b20ef3fc7cc5b00c7e3e5a714468a2ea583b",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Join us in exploring the top gainers and losers within the dow jones index one hour before the close of the markets on Thursday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1784229003,
                "headline": "Which dow jones stocks are moving on Thursday?"
              },
              {
                "id": 140922733,
                "url": "https://finnhub.io/api/news?id=57316ac4de7d44a44d7551a1220cc88d465156b1c8dd591dd00ed4a3a28c1320",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
                "category": "company",
                "datetime": 1784218203,
                "headline": "Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?"
              },
              {
                "id": 140924212,
                "url": "https://finnhub.io/api/news?id=f1a83df4a460a5536afadd68c6d8b67158a8073b9c8875f11b1e6d8dfa1c018b",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2268438699/image_2268438699.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "Johnson & Johnson’s strong Q2 earnings, Spravato sales +41%, and raised 2026 EPS guidance. See why this analysis upgrades JNJ from Sell to Hold.",
                "category": "company",
                "datetime": 1784217215,
                "headline": "I Was Wrong About Johnson & Johnson: Upgrading To Hold (Rating Upgrade)"
              },
              {
                "id": 140920971,
                "url": "https://finnhub.io/api/news?id=6eac034c6914e1faa4d3597b25972ecf5df2fdb6a0f3aad2a0291a50be75e185",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Eli Lilly (LLY) is acquiring AtaiBeckley (ATAI) — a biopharmaceutical company that specializes in psychedelic-based mental health treatments — in a new deal valued at up to $3.8 billion. Mizuho Americas healthcare equity strategist Jared Holz weighs in on this deal and what it represents for M&A in the broader pharma space.",
                "category": "company",
                "datetime": 1784216700,
                "headline": "Eli Lilly is acquiring psychedelic drug developer AtaiBeckley for $3.8 billion"
              },
              {
                "id": 140921023,
                "url": "https://finnhub.io/api/news?id=c841521090eb2d0487f8096cf5c42fe77514039d13a26ba38fdbc226aa19cbce",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Merck snagged the first-ever approval for a PCSK9 pill to lower LDL cholesterol, starting a new rivalry with injection-makers.",
                "category": "company",
                "datetime": 1784216357,
                "headline": "Merck Snags A First-Of-Its-Kind Approval, And Shares Jump"
              },
              {
                "id": 140919686,
                "url": "https://finnhub.io/api/news?id=73e8666060b1415c53da17946bd06f234dc80c8765b33ed82a66e02cf0745fc2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "While the market focuses on a single class of blockbuster drugs, a different story is unfolding inside the company. Lilly’s immunology, oncology, and neuroscience medicines are quietly compounding at a blistering pace. These other therapeutic areas collectively grew by 160% last quarter, a rate that suggests a much broader growth engine is taking shape.",
                "category": "company",
                "datetime": 1784207994,
                "headline": "What Could Push LLY Stock Higher From Here?"
              },
              {
                "id": 140919808,
                "url": "https://finnhub.io/api/news?id=9f49b8a6e7640a41f99b1c8bfc28e099d45c10878a320d2650880060055de93e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Merck snagged the first-ever approval for a PCSK9 pill to lower LDL cholesterol, starting a new rivalry with injection-makers.",
                "category": "company",
                "datetime": 1784207534,
                "headline": "Dow Jones' Merck Snags A First-Of-Its-Kind Approval, And Jumps"
              },
              {
                "id": 140921681,
                "url": "https://finnhub.io/api/news?id=3d6b88aa16f27ea2466e52cf5ac477ead380ed462ce56fc41c2e4583fae31688",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2175574079/image_2175574079.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "SCHD is beating the S&P 500 with a 3.2%+ yield, low beta and defensive sector mix. Learn more about SCHD ETF here.",
                "category": "company",
                "datetime": 1784204843,
                "headline": "SCHD: Your ETF To Hide From The AI Bottleneck Bust"
              },
              {
                "id": 140919811,
                "url": "https://finnhub.io/api/news?id=12d3e8fb22281e211a912d0e9096c6e537c6d8e683867a1bce697f16ecc10d27",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "It’s the first pill that lowers blood cholesterol far better than statins—medicines that a quarter of adults take to reduce their risk of heart attack and stroke.",
                "category": "company",
                "datetime": 1784204220,
                "headline": "Merck Stock Rises After U.S. Approval for Powerful Cholesterol-Cutting Pill"
              },
              {
                "id": 140918861,
                "url": "https://finnhub.io/api/news?id=7877303fb718b2579c613cce560673cb9c26ae710beefbc833cb3e4474640c02",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "It’s the first pill that lowers blood cholesterol far better than statins—medicines that a quarter of adults take to reduce their risk of heart attack and stroke.",
                "category": "company",
                "datetime": 1784198700,
                "headline": "Merck Gets Approval for Powerful Cholesterol-Cutting Pill"
              },
              {
                "id": 140910531,
                "url": "https://finnhub.io/api/news?id=57000288ae8e34864fe003c9dc01032ef3345e614ac1f58d27e5e9465af2590c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1365641802/image_1365641802.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "AstraZeneca PLC Q2 2026 preview: revenue growth, Enhertu sales surge and EU approval, plus risk/reward after Wainua trial setback. Click for this AZN stock update.",
                "category": "company",
                "datetime": 1784120082,
                "headline": "AstraZeneca's Oncology Engine Keeps Running Despite Wainua Setback"
              },
              {
                "id": 140904283,
                "url": "https://finnhub.io/api/news?id=9febfa3e97d1f8a39dfd518043a89e00e344fbdbdef1391c6d7ba9ff3285985c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (AMGN) closed the most recent trading day at $355.25, moving 1.44% from the previous trading session.",
                "category": "company",
                "datetime": 1784065802,
                "headline": "Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know"
              },
              {
                "id": 140901439,
                "url": "https://finnhub.io/api/news?id=64cd56311f93e5171b803be30ef3da8f9f5b6d1c652a2a55be30635d893b79a0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "In the world of big pharma, one company is both the star performer and the most expensive name on the marquee, forcing investors to ask if the price of admission is simply too high.",
                "category": "company",
                "datetime": 1784051674,
                "headline": "What Lilly's Peer-Beating Numbers Cost You"
              },
              {
                "id": 140898965,
                "url": "https://finnhub.io/api/news?id=cabe65425881223e34efd5bb71098208aeb614bd56b2e75936131543a3ffbdda",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Wondering what's happening in today's session for the dow jones index? Stay informed with the top movers within the dow jones index on Tuesday.",
                "category": "company",
                "datetime": 1784047204,
                "headline": "Top dow jones movers in Tuesday's session"
              },
              {
                "id": 140898221,
                "url": "https://finnhub.io/api/news?id=a5052686d64fade991382304b35ce4aaa4ced4362c7202aef97d0f976c633d82",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Pfizer (NYSE: PFE) and Amgen (NASDAQ: AMGN) both reported Q1 2026 results this quarter, and the numbers reveal two very different bets on the future of oncology. Pfizer is monetizing its Seagen deal today. Amgen is defending a biosimilar cliff while spending to rebuild growth from scratch. Padcev Carries Pfizer. Biosimilars Bite Amgen. Pfizer’s oncology ... Pfizer Vs. Amgen: Bet That Pfizer’s Seagen Integration Leads to Long-Term Oncology Alpha Over Amgen",
                "category": "company",
                "datetime": 1784044263,
                "headline": "Pfizer Vs. Amgen: Bet That Pfizer’s Seagen Integration Leads to Long-Term Oncology Alpha Over Amgen"
              },
              {
                "id": 140899860,
                "url": "https://finnhub.io/api/news?id=d1bf38292b1076f8135cbb61c6256a19bcc5703dd35a0c60257319f3b803c51c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "HRMY vs. AMGN: Which Stock Is the Better Value Option?",
                "category": "company",
                "datetime": 1784043604,
                "headline": "HRMY vs. AMGN: Which Stock Is the Better Value Option?"
              },
              {
                "id": 140898029,
                "url": "https://finnhub.io/api/news?id=386cc1201a7319eeb23e507abedf0a96e669057f4cebeeb85a7fb0d0b5758115",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The company is making a fundamental pivot you might have missed, and it has nothing to do with building more vehicles.",
                "category": "company",
                "datetime": 1784042689,
                "headline": "What If the Car Is No Longer the Point For Tesla Stock?"
              },
              {
                "id": 140898223,
                "url": "https://finnhub.io/api/news?id=a682f098548ccbc4e3f62768d931b92fe8a0ed333d7ac2a35cc038786e82d08b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen stock has delivered a strong 73.5% return over the last three years, and the current checks suggest a mixed picture on value, with an intrinsic value estimate from a Discounted Cash Flow (DCF) model pointing to upside while market based multiples look closer to fair. Over three years, Amgen has returned 73.5%, which puts recent price action in focus when judging how much upside may still be left in the valuation. The recent court decision blocking Colorado's proposed price cap on...",
                "category": "company",
                "datetime": 1784042024,
                "headline": "Amgen (AMGN) Stock May Be 47% Undervalued After Enbrel Price Cap Ruling"
              },
              {
                "id": 140895304,
                "url": "https://finnhub.io/api/news?id=157f7c5da8ff0a5e4f2a825c575e945d68e2085c942ec86685abf546d23b7c5a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Opportunities include integrating cardio-renal strategies, aligning therapies with real-world evidence, leveraging site-of-care economics, and enhancing supply resilience amid tariff influences. Late Stage Chronic Kidney Disease Therapeutics Market Late Stage Chronic Kidney Disease Therapeutics Market Dublin, July 14, 2026 (GLOBE NEWSWIRE) -- The \"Late Stage Chronic Kidney Disease Therapeutics Market - Global Forecast 2026-2032\" has been added to ResearchAndMarkets.com's offering.The Late Stage",
                "category": "company",
                "datetime": 1784016960,
                "headline": "Advancements in CKD Care: How New Therapies from AstraZeneca, Johnson & Johnson, Novartis, Bayer, and Amgen Are Changing the Landscape"
              },
              {
                "id": 140889583,
                "url": "https://finnhub.io/api/news?id=f13399f677cd7c71aafcdc84abe74809c39d947570bc4629e20caf0d44034b59",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Curious about the dow jones stocks that are in motion on Monday? Join us as we explore the top movers within the dow jones index during today's session.",
                "category": "company",
                "datetime": 1783969804,
                "headline": "Uncover the latest developments among dow jones stocks in today's session."
              },
              {
                "id": 140889945,
                "url": "https://finnhub.io/api/news?id=95d8385b175893b33fb0ee564169a6c921967c8c1442a31b90be4aac1c4c6259",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.",
                "category": "company",
                "datetime": 1783965519,
                "headline": "2 Profitable Stocks with Solid Fundamentals and 1 We Turn Down"
              },
              {
                "id": 140888428,
                "url": "https://finnhub.io/api/news?id=ed15eb87356bea39d17c294679a13f32dbb5cc7c416f7aa1579ca7722654403b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "For investors seeking exposure to biotechnology's future, Incyte presents a clearer forward picture of accelerating growth, while the larger Regeneron asks for more faith in its pipeline.",
                "category": "company",
                "datetime": 1783964231,
                "headline": "Own Regeneron For Biotech Growth? Incyte Is Making Its Case."
              },
              {
                "id": 140887734,
                "url": "https://finnhub.io/api/news?id=125afec3135f0eabea38274af6bc3b39ef8f893650eb6807f2ca927064936ff0",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Stay updated with the movement of dow jones stocks in today's session. Discover which dow jones stocks are making waves on Monday.",
                "category": "company",
                "datetime": 1783960804,
                "headline": "Discover which dow jones stocks are making waves on Monday."
              },
              {
                "id": 140889741,
                "url": "https://finnhub.io/api/news?id=e15b38c19ffe851249b8901824d900153c36ef0469af5b5e52263879973430f8",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "UBS  analyst Michael Yee   maintains Amgen (NASDAQ:AMGN) with a Buy and raises the price target from $400 to $420.",
                "category": "company",
                "datetime": 1783952534,
                "headline": "UBS Maintains Buy on Amgen, Raises Price Target to $420"
              },
              {
                "id": 140885768,
                "url": "https://finnhub.io/api/news?id=beb87ad176efb9fdff630913987b4267d509627241251c66ccf0cea69cf5af22",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "At $1,189, Eli Lilly (LLY) looks set up for roughly 76% of upside over the next three years under a conservative scenario. That is a move large enough to justify digging into where it comes from. Revenue compounding does the work, but the multiple takes a meaningful cut along the way. Here is the operational reality the math is built on.",
                "category": "company",
                "datetime": 1783948326,
                "headline": "How Does LLY Stock Reach $2,100?"
              },
              {
                "id": 140886989,
                "url": "https://finnhub.io/api/news?id=4c1ffdb45bd9d7ee28a1adbef24633e34fffe95bbd084f485707484e9448b6f1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
                "category": "company",
                "datetime": 1783947604,
                "headline": "Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It"
              },
              {
                "id": 140889742,
                "url": "https://finnhub.io/api/news?id=89368340ea0d09f60ea6fbb808f3e12a869c317e8a738cbcfbd896e0c5b24125",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Guggenheim  analyst Vamil Divan   maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price target from $340 to $343.",
                "category": "company",
                "datetime": 1783932221,
                "headline": "Guggenheim Maintains Neutral on Amgen, Raises Price Target to $343"
              },
              {
                "id": 140888412,
                "url": "https://finnhub.io/api/news?id=93f5340e5800f1d6cc38b15c4dfc371cb4de26812bf2bca911cd8e2923379f1a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "FTSE 100 up 1 point at 10,498 Oil prices hit 3-week high amid new US-Iran strikes Plus500, PageGroup, Oxford Nanopore post numbers 5.15pm: Investors cautious As investors eyed geopolitical developments, London stocks finished the day little changed, up 1 point at 10,498. The US’...",
                "category": "company",
                "datetime": 1783923540,
                "headline": "FTSE 100 Live: Stocks flat as Trump says US to be 'guardian of Hormuz strait'"
              },
              {
                "id": 140865011,
                "url": "https://finnhub.io/api/news?id=da214c6fd8d23b4dd37c80c7d483172cf970e4a98b72e72eb896b08e27b9522a",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Let's have a look at the top dow jones gainers and losers one hour before the close of the markets of today's session.",
                "category": "company",
                "datetime": 1783710603,
                "headline": "Top dow jones movers in Friday's session"
              },
              {
                "id": 140854393,
                "url": "https://finnhub.io/api/news?id=8aa183e4eb382bb57aaedb6480970e58abb6cea03f36efc9ca36b62b299e7a58",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Stay updated with the movement of dow jones stocks in today's session. Discover which dow jones stocks are making waves on Thursday.",
                "category": "company",
                "datetime": 1783624203,
                "headline": "Exploring the top movers within the dow jones index during today's session."
              },
              {
                "id": 140853675,
                "url": "https://finnhub.io/api/news?id=bb56a4228bb6a02bad1f4c2d8374cd57c6a024bdeaf4958be35cb75cb57db557",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the 15 Best NASDAQ 100 Stocks to Buy Other Than SpaceX. On July 7, 2026, Truist raised the firm’s price target on Amgen Inc. (NASDAQ:AMGN) to $340 from $327 as part of a broader Q2 earnings preview for biotech. Truist said it expects a rebound from a traditionally softer […]",
                "category": "company",
                "datetime": 1783615451,
                "headline": "Truist Raises its Price Target on Amgen (AMGN)"
              },
              {
                "id": 140852952,
                "url": "https://finnhub.io/api/news?id=0d784b8700baa9952e6e2725c6aabb3cd5fb07a43fc8a07af17486eee4f010a8",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Let's have a look at the top dow jones gainers and losers in the middle of the day of today's session.",
                "category": "company",
                "datetime": 1783615204,
                "headline": "Top dow jones movers in Thursday's session"
              },
              {
                "id": 140853484,
                "url": "https://finnhub.io/api/news?id=a37245c725bdaa7038adeca694577bae64e2a1096e408d1811dd4be0d93626e9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The Health Care Select Sector SPDR Fund (NYSEARCA:XLV) is the default healthcare allocation for millions of investors, and for good reason. XLV owns the entire S&P 500 healthcare complex in one ticker: insurers, device makers, biotech, and Big Pharma. It has returned 21.61% over the past year and 159.84% over ten years. If the reason ... Two Drugmakers Own 90% of the Obesity Boom. One Fund Owns Both for 0.59%",
                "category": "company",
                "datetime": 1783613908,
                "headline": "Two Drugmakers Own 90% of the Obesity Boom. One Fund Owns Both for 0.59%"
              },
              {
                "id": 140852010,
                "url": "https://finnhub.io/api/news?id=553e10dc88f8db461878d38f0666f117101c8f854c6a22e5273fb7ce1784b80d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "CNBC’s Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter. Instead, he highlighted a group he says has quietly become the market’s leader. “There is a move in biotech that we have not talked about at all that is really extraordinary, and particularly since the change at the head of the FDA,” ... Jim Cramer Says Biotech is The Hottest Group in The Market Right Now",
                "category": "company",
                "datetime": 1783611325,
                "headline": "Jim Cramer Says Biotech is The Hottest Group in The Market Right Now"
              },
              {
                "id": 140852126,
                "url": "https://finnhub.io/api/news?id=018b9f7253bc4e17d4c43637f9d4ef486eb81a27b4c5665faefb42064eb3b9b0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Get paid a guaranteed income now on your Amgen shares, which you keep no matter what, in exchange for agreeing to sell at a price that's already a win.",
                "category": "company",
                "datetime": 1783609118,
                "headline": "Make Your AMGN Shares Pay You 8.7% While You Hold Them"
              },
              {
                "id": 140852223,
                "url": "https://finnhub.io/api/news?id=f8b33ea327d0c4ea3cfcb1e73a6ac41473d1a77d2481f032c45fd6748adff54a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen trades at $365.22 per share and has stayed right on track with the overall market, gaining 12% over the last six months. At the same time, the S&P 500 has returned 7.7%.",
                "category": "company",
                "datetime": 1783606380,
                "headline": "Amgen (AMGN): Buy, Sell, or Hold Post Q1 Earnings?"
              },
              {
                "id": 140850358,
                "url": "https://finnhub.io/api/news?id=840cbddb211ad3a61dbdba03223eb2cf874f8da5b0b48f025699b494ac5f7406",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2256411028/image_2256411028.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "Novo Nordisk regains competitive ground in obesity with the strong launch of the Wegovy pill, reversing some of the recent underperformance against Eli Lilly.",
                "category": "company",
                "datetime": 1783586769,
                "headline": "Novo Nordisk's Wegovy Pill Escalates Eli Lilly Rivalry"
              },
              {
                "id": 140844150,
                "url": "https://finnhub.io/api/news?id=9f5dbca0860c023f09bac87bc2eaea6090b20867b27cdb9d40ab07f3c5d97a89",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Wednesday.",
                "category": "company",
                "datetime": 1783537803,
                "headline": "Stay informed with the top movers within the dow jones index on Wednesday."
              },
              {
                "id": 140841778,
                "url": "https://finnhub.io/api/news?id=c1d9e054f88af7cc76ad45c92c50beba49c8aebc5a78167930dc9e5fb87ef4c1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "For shareholders, the coming year isn't about a small gain or loss but a potential journey to one of two very different destinations.",
                "category": "company",
                "datetime": 1783524984,
                "headline": "The Wide Divide Ahead For Eli Lilly Stock"
              },
              {
                "id": 140841649,
                "url": "https://finnhub.io/api/news?id=46cf1067762772bdaff0bf3cd43eb85b6816d116b9c6119f06b2aaa77d698dba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather th",
                "category": "company",
                "datetime": 1783523510,
                "headline": "Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says"
              },
              {
                "id": 140856234,
                "url": "https://finnhub.io/api/news?id=7ff17473d0b995e64bf53a308a893d182fcad9306341c6c863ac64e6cb4f3d23",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Morgan Stanley  analyst Terence Flynn   maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and lowers the price target from $340 to $333.",
                "category": "company",
                "datetime": 1783513399,
                "headline": "Morgan Stanley Maintains Equal-Weight on Amgen, Lowers Price Target to $333"
              },
              {
                "id": 140837499,
                "url": "https://finnhub.io/api/news?id=4ab3ef6ff1126cf165b77a351fd1ead442295ca99d8f5f60aa888748bc037095",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (AMGN) has moved into focus after initiating voluntary nationwide recalls of certain Corlanor and Sensipar tablet lots due to foreign substances and CGMP deviations, prompting investors to reassess drug quality and compliance risks. See our latest analysis for Amgen. Against this recall backdrop, Amgen’s recent momentum has stayed intact, with a 30 day share price return of 5.30% and a year to date share price return of 12.35%. The 1 year total shareholder return of 27.66% and 3 year...",
                "category": "company",
                "datetime": 1783480559,
                "headline": "Amgen (AMGN) Recalls Put Its Valuation Story Back In Focus"
              },
              {
                "id": 140836508,
                "url": "https://finnhub.io/api/news?id=37ff8553ddc0dcf4fb1001b928b477f969b833921e9c928c1572dddb2f11f996",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "In early June 2026, a federal judge granted Amgen a preliminary injunction blocking Colorado’s proposed 70% price cap on its rheumatoid arthritis drug Enbrel, while the company also initiated several voluntary Class II recalls of Corlanor and Sensipar batches in the United States over foreign substances and CGMP deviations. This mix of regulatory relief on Enbrel’s pricing and ongoing quality-related recalls raises important questions about how investors weigh pricing power against...",
                "category": "company",
                "datetime": 1783462199,
                "headline": "Did Enbrel’s Price Cap Reprieve and New Recalls Just Rebalance Amgen’s (AMGN) Risk‑Reward Profile?"
              },
              {
                "id": 140834287,
                "url": "https://finnhub.io/api/news?id=c3ec7e77c123977d904fa26108fc87877fbe13b19021cdb12dda964dd339d036",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Near-term headwinds could sink the stock, but there is more to the story.",
                "category": "company",
                "datetime": 1783451100,
                "headline": "How Safe Is Amgen's Dividend?"
              },
              {
                "id": 140834288,
                "url": "https://finnhub.io/api/news?id=f317b715da068c31c835229a3852f5af3d01f5d3ca3d0343fdbecb1a446a57db",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen has initiated several product recalls in the US for Sensipar (cinacalcet) and Corlanor (ivabradine). The recalls involve multiple lots, dosage strengths, and large product quantities distributed nationwide. Regulators cited current good manufacturing practice (CGMP) deviations and contamination concerns affecting certain products. The pattern of recurring recalls extends beyond a single isolated lot or event. For investors following Amgen, ticker NasdaqGS:AMGN, the scale and...",
                "category": "company",
                "datetime": 1783448440,
                "headline": "Amgen (AMGN) Recalls Sensipar And Corlanor In Broad US Quality Sweep"
              },
              {
                "id": 140832952,
                "url": "https://finnhub.io/api/news?id=a07c9c4cef97cce487e30f32d0b1056e59bd7c136669ff319a0aef87895b94ee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "On CNBC’s Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing that the sector could be entering a new wave of mergers and acquisitions as the regulatory environment becomes more favorable for dealmaking. “There is a move in biotech that we have not ... Jim Cramer Calls Biotech “The Hottest Group in the Market” as He Predicts “Deals Are Going to Be Flooding the Market”",
                "category": "company",
                "datetime": 1783441817,
                "headline": "Jim Cramer Calls Biotech “The Hottest Group in the Market” as He Predicts “Deals Are Going to Be Flooding the Market”"
              },
              {
                "id": 140834754,
                "url": "https://finnhub.io/api/news?id=4d89872b004dca14a6870de61f5ef1d698aaa61a1b2ed089f25c7558e3881f78",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_4.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 1.05% on an annualized basis producing an average annual return of 13.3%. Currently, Amgen has a market capitalization of $202.05 billion.",
                "category": "company",
                "datetime": 1783425016,
                "headline": "If You Invested $100 In Amgen Stock 15 Years Ago, You Would Have This Much Today"
              },
              {
                "id": 140829567,
                "url": "https://finnhub.io/api/news?id=736265c3bcf026a1c9eaf58c5f2d746749e1e592e9b0699d74bef818c0ec74df",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2183695394/image_2183695394.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "Novartis bolsters its ADC pipeline via Myricx Bio deal, while Avidity del-brax and Ionis pelacarsen near pivotal readouts—see what to watch now.",
                "category": "company",
                "datetime": 1783413652,
                "headline": "Novartis' Pipeline Building Continues, Pelacarsen Readout Coming Soon"
              },
              {
                "id": 140834755,
                "url": "https://finnhub.io/api/news?id=954c3b11a86618793121eb702fcac18f56ae0b8c432b6526a2b27617d9c888a3",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Truist Securities  analyst Gregory Renza   maintains Amgen (NASDAQ:AMGN) with a Hold and raises the price target from $327 to $340.",
                "category": "company",
                "datetime": 1783410126,
                "headline": "Truist Securities Maintains Hold on Amgen, Raises Price Target to $340"
              },
              {
                "id": 140825384,
                "url": "https://finnhub.io/api/news?id=c4dd0835023ad80e7ee0aeb355133f279a69002b6dea4bfd2e8e265f193a57ae",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (AMGN) closed the most recent trading day at $366.44, moving 2.06% from the previous trading session.",
                "category": "company",
                "datetime": 1783375203,
                "headline": "Amgen (AMGN) Stock Dips While Market Gains: Key Facts"
              },
              {
                "id": 140824128,
                "url": "https://finnhub.io/api/news?id=755bfac8086b55458ed003b38133dd776e18096e6e6946c3c4a4bc64ae17e627",
                "image": "https://www.chartmill.com/images/uploads/CM_Aftermarket_Movers_Small_free_e077945a19.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top S&P500 gainers and losers shaping the post-market sentiment.",
                "category": "company",
                "datetime": 1783371901,
                "headline": "Which S&P500 stocks are showing activity after the closing bell on Monday?"
              },
              {
                "id": 140824417,
                "url": "https://finnhub.io/api/news?id=186fff17d3fd8c74d0ea37961a030197361df88d1472c2d1cb324314c6a059a8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Before the share price caught on, the drugmaker was dealing with a problem most companies only dream of, and it was the clearest sign a surge was building.",
                "category": "company",
                "datetime": 1783369384,
                "headline": "What Eli Lilly Stock Said When It Had Too Much Business"
              },
              {
                "id": 140823275,
                "url": "https://finnhub.io/api/news?id=aacc08c69cab6b9db8a0b9bbabb6718315106d78c1d7f115fc1eb8077d774c13",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Get insights into the dow jones index performance on Monday. Explore the top gainers and losers within the dow jones index in today's session.",
                "category": "company",
                "datetime": 1783365003,
                "headline": "Explore the top gainers and losers within the dow jones index in today's session."
              },
              {
                "id": 140822547,
                "url": "https://finnhub.io/api/news?id=1afd47739aab53e639af99f3c3555fd4cc84a896ce09a6e979e29cf1ad07ba85",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "By Karen Roman VERAXA Biotech AG (Nasdaq: VRXA) said it expects BiTAC molecules to be the company’s main value drivers and to dominate its pipeline development in the upcoming years, hence receiving VERAXA’s main share of investments to have a first BiTAC-T cell engager candidate ready by early 2028. The company stated its half-year progress […] The post The Cancer Therapy Strategy VERAXA Is Betting the Company On appeared first on ExecEdge.",
                "category": "company",
                "datetime": 1783353653,
                "headline": "The Cancer Therapy Strategy VERAXA Is Betting the Company On"
              },
              {
                "id": 140822548,
                "url": "https://finnhub.io/api/news?id=3f802ddbff655ce00399dc8e1c1726f92a0c773683455a621cf019fcdf411f9e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (AMGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.",
                "category": "company",
                "datetime": 1783353604,
                "headline": "Amgen (AMGN) Upgraded to Buy: What Does It Mean for the Stock?"
              },
              {
                "id": 140820483,
                "url": "https://finnhub.io/api/news?id=94fc5e1555bc065d9d774254f722bc9d84522a9c3c15d091f554e0694959ee94",
                "image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Looking for opportunities in today's market? Check out the S&P500 gap up and gap down stocks on Monday and stay ahead of the market trends.",
                "category": "company",
                "datetime": 1783348501,
                "headline": "Which S&P500 stocks are gapping on Monday?"
              },
              {
                "id": 140821116,
                "url": "https://finnhub.io/api/news?id=f72a77038623bc77a6c8773d2ab4296d457405fee3785077e89b3721ca96898c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Here is how Allarity Therapeutics, Inc. (ALLR) and Amgen (AMGN) have performed compared to their sector so far this year.",
                "category": "company",
                "datetime": 1783345203,
                "headline": "Is Allarity Therapeutics, Inc. (ALLR) Stock Outpacing Its Medical Peers This Year?"
              },
              {
                "id": 140821003,
                "url": "https://finnhub.io/api/news?id=9389013d71fe7c5c0a0407bec65a9b6249337d8cc91deeb91588cd3ef1be3380",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "11:02am: Week ahead Wall Street enters the week with investors focused on the start of the second quarter earnings season, the Federal Reserve's latest meeting minutes and a handful of economic releases that could offer fresh insight into the outlook for interest rates, economic growth and...",
                "category": "company",
                "datetime": 1783339140,
                "headline": "Nasdaq starts strong as 'Trump accounts' launch, Dow dragged down"
              },
              {
                "id": 140821903,
                "url": "https://finnhub.io/api/news?id=50d9afed06e6b3f532ca2d55665edd1038daea96dd4f3c25a97bc0e80ba7cea9",
                "image": "https://image.cnbcfm.com/api/v1/image/108330802-17833443451783344342-46993064617-1080pnbcnews.jpg?v=1783344344&w=1920&h=1080",
                "source": "CNBC",
                "related": "AMGN",
                "summary": "CNBC’s Jim Cramer delivers his daily Mad Dash.",
                "category": "company",
                "datetime": 1783330243,
                "headline": "Cramer’s Mad Dash: iShares Biotechnology ETF"
              },
              {
                "id": 140824864,
                "url": "https://finnhub.io/api/news?id=336bdc2374a9a1558ae5df846202007ab6b727167d187e2a28c007cb78a261a9",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Cantor Fitzgerald  analyst Carter Gould   reiterates Amgen (NASDAQ:AMGN) with a Neutral and maintains $350 price target.",
                "category": "company",
                "datetime": 1783328173,
                "headline": "Cantor Fitzgerald Reiterates Neutral on Amgen, Maintains $350 Price Target"
              },
              {
                "id": 140820581,
                "url": "https://finnhub.io/api/news?id=d78c036b50e519b565344311a0d3db62f47be1f8e694fcce308d14cfbc7f99d2",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/05/Elizabeth-Warren.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Elizabeth Warren warns Trump's law pushed children off Medicaid and CHIP in many states, while also challenging TrumpRx's impact on drug costs.",
                "category": "company",
                "datetime": 1783260507,
                "headline": "Warren Says Trump's Law Pushed 2 Million-Plus Children Off Medicaid, CHIP Across States"
              },
              {
                "id": 140802868,
                "url": "https://finnhub.io/api/news?id=4d15cef700ca937e9ae7d6be654d5ff103cc152b3f8c9d1a486012147648ec57",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "RHHBY announces positive phase III Krascendo 1 results for divarasib in KRAS G12C NSCLC, showing PFS and OS gains versus approved inhibitors.",
                "category": "company",
                "datetime": 1783100520,
                "headline": "Roche Reports Positive Results From Head-to-Head Study on NSCLC Drug"
              },
              {
                "id": 140801050,
                "url": "https://finnhub.io/api/news?id=47b38ede09683f60c6412e4fe196383507b39e54ac0a2552edb25b8b0c07a048",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The biggest names in tech, e-commerce, and digital transformation are in the Nasdaq 100 (^NDX), but only a few are leading the pack. Some companies in this index are proving their resilience and expanding their competitive advantages.",
                "category": "company",
                "datetime": 1783096446,
                "headline": "3 Nasdaq 100 Stocks to Research Further"
              },
              {
                "id": 140796503,
                "url": "https://finnhub.io/api/news?id=03dd84a049fa940ed811f34542ecc83d6d561022c912915f3b233b5947039ce0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Shares of biotech company Amgen (NASDAQ:AMGN) jumped 3.1% in the afternoon session after the company received a favorable court ruling that blocked a first-of-its-kind state price cap on its blockbuster drug, Enbrel.",
                "category": "company",
                "datetime": 1783038504,
                "headline": "Amgen (AMGN) Stock Is Up, What You Need To Know"
              },
              {
                "id": 140794946,
                "url": "https://finnhub.io/api/news?id=3b674938115048840a15d92c2b6216c892d29831d83a8bf099f29179daccf517",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Stock Market Today: The Dow Jones index bolts higher in a mixed finish Thursday. Tesla stock skids despite strong quarterly deliveries.",
                "category": "company",
                "datetime": 1783026126,
                "headline": "Stock Market Today: Dow Runs 590 Points To New High But Meta, Chip, Optical Stocks Slammed"
              },
              {
                "id": 140792024,
                "url": "https://finnhub.io/api/news?id=c45e2e2f6f76838ff4814d162c1a0f8fd60f296f67f89848bbcd0a92bc52086f",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Join us in exploring the top gainers and losers within the dow jones index in the middle of the day on Thursday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1783010403,
                "headline": "Stay informed with the top movers within the dow jones index on Thursday."
              },
              {
                "id": 140791455,
                "url": "https://finnhub.io/api/news?id=2b80147d01736900f7f3e4d56b28b4d3666002c78a71249b15112e15c38808bb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The Phase 3 trial compared Roche’s divarasib with treatments sold by Amgen and Bristol Myers in patients with non-small cell lung cancer.",
                "category": "company",
                "datetime": 1782987579,
                "headline": "Roche KRAS drug succeeds in head-to-head lung cancer study"
              },
              {
                "id": 140790529,
                "url": "https://finnhub.io/api/news?id=876c3db4f0d604dedad75b16adaa36eb7e43046ddc12b8b5a496ca3d3a61c3bb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Experimental drug, divarasib, showed meaningful improvements in both patients’ overall survival and the time they survived without the disease worsening.",
                "category": "company",
                "datetime": 1782971400,
                "headline": "Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial"
              },
              {
                "id": 140783353,
                "url": "https://finnhub.io/api/news?id=8d8d4dbcd75e54bc1136dbce779a2713eac74a23a63c39b81cb0c347fdd45387",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Wednesday.",
                "category": "company",
                "datetime": 1782933003,
                "headline": "Which dow jones stocks are moving on Wednesday?"
              },
              {
                "id": 140780654,
                "url": "https://finnhub.io/api/news?id=1bd01f8e61ef51ebcb51cb5b0359bbb686d74196259eb0aebb6161b83b544b3e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "AMGN stands out compared to Biogen given its broader product portfolio, pipeline depth and steadier growth outlook despite patent and competition risks.",
                "category": "company",
                "datetime": 1782911040,
                "headline": "Amgen or Biogen: Which Biotech Stock Appears Better Poised?"
              },
              {
                "id": 140778821,
                "url": "https://finnhub.io/api/news?id=0d342a2374488970403c9efc18a623564087ed8bebef61cbafc7424678904311",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "This further weakens Amgen’s case for Tavneos’ continued use on the market as the drug comes under intense regulatory scrutiny.",
                "category": "company",
                "datetime": 1782903980,
                "headline": "Medical journal retracts Tavneos pivotal paper amid wider regulatory clampdown"
              },
              {
                "id": 140778787,
                "url": "https://finnhub.io/api/news?id=4059fc2e083439040224e3484f51bebf3b6108688736c2ad1aae17b7fcfac049",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Neil Gallagher, MD, PhD, joins with over 25 years clinical development experience, having contributed to multiple commercial therapeutics across haematology and oncologyHis appointment will strengthen Step Pharma’s board as it advances dencatistat across three clinical programmes for essential thrombocythaemia (ET), lymphoma and solid tumours. Saint-Genis-Pouilly, France, 1 July 2026 – Step Pharma (“the Company”), the global leader in CTPS1 inhibition for targeted cancer treatment, today announc",
                "category": "company",
                "datetime": 1782903600,
                "headline": "Step Pharma announces the appointment of Neil Gallagher as Non-Executive Director"
              },
              {
                "id": 140778823,
                "url": "https://finnhub.io/api/news?id=66e1f0c32282c29315b4774f29e0814ebe766a101f8f3b13b4a0769663f55135",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen Inc. (NASDAQ:AMGN) ranks among the top NASDAQ stocks for retirement. On June 16, Mizuho increased its price target for Amgen Inc. (NASDAQ:AMGN) to $303 from $295 while keeping a Neutral rating on the company’s shares, with the firm highlighting MariTide and olpasiran as crucial focal points for the company. Mizuho said that Novartis and […]",
                "category": "company",
                "datetime": 1782900908,
                "headline": "Mizuho Highlights Amgen (AMGN) Pipeline Potential With MariTide and Olpasiran"
              },
              {
                "id": 140780264,
                "url": "https://finnhub.io/api/news?id=90cbe8f7c2be5ad4521a23ea4668dff47835f01f7d0327a9b12e844613a71a0c",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/01/Micron-Technology-Logo-Displayed-On-A-Mo.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "CNBC Final trades: Lebenthal picks Micron, Snipe chooses Palo Alto, Brown expects Apple's good second half, Terranova recommends Amgen.",
                "category": "company",
                "datetime": 1782892508,
                "headline": "Micron, Palo Alto, Apple And A Health Care Stock On CNBC’s ‘Final Trades’"
              },
              {
                "id": 140777698,
                "url": "https://finnhub.io/api/news?id=ad5d9322224b7fd6c119cf9c43faa3b55bf44c4daf1f863bcd8bb4ee506fd7a0",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215519735/image_2215519735.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "The top 25 stocks average a 3.09% yield, ~12% undervaluation, and a projected 14.44% future CAGR. Check out the July 2026 dividend stock watchlist here.",
                "category": "company",
                "datetime": 1782874510,
                "headline": "Top 25 High-Yield Dividend Stocks For July 2026"
              },
              {
                "id": 140775311,
                "url": "https://finnhub.io/api/news?id=6732d90f14b871e755b5c2cb0f55c931a095b07864a64a0872cef0a7ebe9824d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended revoking Amgen’s Tavneos marketing authorization in the EU. The recommendation concerns Tavneos, a treatment for certain autoimmune conditions, and focuses on its continued approval in European markets. This regulatory step introduces fresh questions for investors following Amgen (NasdaqGS:AMGN) beyond earlier topics such as valuation and patent issues. For investors watching Amgen, this...",
                "category": "company",
                "datetime": 1782850030,
                "headline": "Amgen (AMGN) Faces EU Push To Revoke Tavneos Approval"
              },
              {
                "id": 140775621,
                "url": "https://finnhub.io/api/news?id=ba4bee7973b33d1ab47b1c5bd0bd439d3450cca266c881f93fcb051a7eb2bf2d",
                "image": "",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "",
                "category": "company",
                "datetime": 1782842568,
                "headline": "Verizon Leads July's 'Safer' Dogs Of The Dow; Nike Near 'Ideal'"
              },
              {
                "id": 140773561,
                "url": "https://finnhub.io/api/news?id=84a17f90433d6da451f1b66b4f3ae238e756603f3ffcfefe2c8379265a8cfde8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "FDA and European regulators continue seeking Tavneos withdrawal as Amgen contests the proposed market action.",
                "category": "company",
                "datetime": 1782836902,
                "headline": "Amgen Faces Fresh Pressure After NEJM Retracts Trial Behind $459 Million Drug"
              },
              {
                "id": 140781831,
                "url": "https://finnhub.io/api/news?id=e9d9d0093a1a35a7347fec3fa722f72d3721be9b7dded6d9a52040286afc3a6a",
                "image": "https://image.cnbcfm.com/api/v1/image/108328818-17828389181782838903-46870682799-1080pnbcnews.jpg?v=1782838917&w=1920&h=1080",
                "source": "CNBC",
                "related": "AMGN",
                "summary": "The Investment Committee give you their top stocks to watch for the second half.",
                "category": "company",
                "datetime": 1782824688,
                "headline": "Final Trades: Apple, Palo Alto Networks, Micron and Amgen"
              },
              {
                "id": 139964018,
                "url": "https://finnhub.io/api/news?id=19c9a624f40e7c94aa157363d46f13bf5b0dcd2b7a469a000e0370dee136acd7",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "",
                "category": "company",
                "datetime": 1782824433,
                "headline": "Live On CNBC, Kevin Simpson Announces Bought More Palo Alto Networks"
              },
              {
                "id": 140772888,
                "url": "https://finnhub.io/api/news?id=690bb55a2c8b143f8e1d40e1055a958d94b6333584adaa6277e8025b314adbd5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "category": "company",
                "datetime": 1782824406,
                "headline": "Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know"
              },
              {
                "id": 140773562,
                "url": "https://finnhub.io/api/news?id=e544fa6878033c1b241c1df236ce2987d27137f7b8360eb95e08ba7a11faec10",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The FDA, through a new approval, gave Viridian's drug a label that some on Wall Street believe makes it well-positioned to compete against Tepezza in the thyroid eye disease market.",
                "category": "company",
                "datetime": 1782819180,
                "headline": "Viridian may have edge over Amgen in eye drug showdown, analysts argue"
              },
              {
                "id": 140772314,
                "url": "https://finnhub.io/api/news?id=e10497ea38e4fbad71eb7072d597a29bb43582fc3c78ed5ce80d21a5cf7c2964",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2194222148/image_2194222148.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "Vertex Pharmaceuticals Incorporated offers predictable CF cash flows and pipeline catalysts in pain, hematology & renal (Pove for IgAN). Click for this VRTX update.",
                "category": "company",
                "datetime": 1782810196,
                "headline": "Vertex Pharmaceuticals Has One Of The Widest And Most Durable Moats In Biotech"
              },
              {
                "id": 140771188,
                "url": "https://finnhub.io/api/news?id=d89de3ba7df12976e9b60409f6dd8f0dfe4fd29c7f82f907b4c144461f420a14",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "If you are wondering whether Amgen stock still offers value at current levels, this article walks through what the numbers are actually saying about the price you see on screen. Amgen shares last closed at US$360.55, with returns of 3.9% over the past week, 7.1% over the past month, 10.0% year to date, 27.8% over one year, 75.7% over three years, and 73.2% over five years. This gives investors plenty of price history to weigh against today’s valuation. Recent attention on Amgen has been...",
                "category": "company",
                "datetime": 1782807306,
                "headline": "Amgen (AMGN) Stock Weighs Strong Run Against Mixed Valuation Signals"
              },
              {
                "id": 140765417,
                "url": "https://finnhub.io/api/news?id=54fca79a72ef6ab10f321f3b9a76224d1539a3dba8e92484bc7fdf1e835ee63d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "This pharma giant's recent run is grabbing headlines, but its long-term behavior tells a more interesting story about portfolio risk.",
                "category": "company",
                "datetime": 1782754652,
                "headline": "Should You Chase The Breakout In Eli Lilly Stock?"
              },
              {
                "id": 140762651,
                "url": "https://finnhub.io/api/news?id=aa2809975315f5f7287a3890cf22490bce48d6c5103b5dc62004e00285d3360c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Jefferies initiated coverage of Quantinuum stock with a buy rating, touting the company's broad hardware and software platform.",
                "category": "company",
                "datetime": 1782745440,
                "headline": "UBS, BofA, Jefferies Start Quantinuum With Buy Ratings On 'Full-Stack' Platform"
              },
              {
                "id": 140761637,
                "url": "https://finnhub.io/api/news?id=5326e97615c7204ba62def7350aa62d2b8bcee64e9218fe8da66c7d201c7764d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Jefferies initiated coverage of Quantinuum stock with a buy rating, touting the company's broad hardware and software platform.",
                "category": "company",
                "datetime": 1782740646,
                "headline": "BofA, Jefferies Start Quantinuum With Buy Ratings On 'Full-Stack' Platform"
              },
              {
                "id": 140767704,
                "url": "https://finnhub.io/api/news?id=7f5cb9b8dcc0930184bcd96269c50e806cdfb09d6bd7d1f8e38cd220d6b27272",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/29/Quantum-Computing-Concept-Revolutionizin.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Shares of Quantinuum slide after rallying since IPO. Analysts weigh in.",
                "category": "company",
                "datetime": 1782734225,
                "headline": "Apollo To Drive Quantinuum Revenue Growth Of 128% Until 2031, Say Bullish Analysts"
              },
              {
                "id": 140764546,
                "url": "https://finnhub.io/api/news?id=705882dfff5c6c4c8fbbd2c2115db7d9b52431d3034f5831e9954e01575f95dd",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/29/Trump-Pressure-Adds-Backdrop.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "FDA approves Viridian Therapeutics' Lumvoa for thyroid eye disease. Immediate commercial launch scheduled with full patient support.",
                "category": "company",
                "datetime": 1782725087,
                "headline": "Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease"
              },
              {
                "id": 140753990,
                "url": "https://finnhub.io/api/news?id=fce43d52df7f57adcf19b0141f93fe4ff31409260163bd796f09da38fba70f7a",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2264471660/image_2264471660.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "Schwab US Dividend Equity ETF offers mature, profitable businesses at a blended P/E of 15.6x, a significant discount to the S&P 500. Click for more on SCHD.",
                "category": "company",
                "datetime": 1782639000,
                "headline": "It's Time To Go All-In On SCHD"
              },
              {
                "id": 140746249,
                "url": "https://finnhub.io/api/news?id=2326d0015cb7cd459a2b10cb2e71b4f1dee0923ac72d78bd2ff2635e7ebf97ef",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "With just 30 components, the Dow's exclusivity is built on industry leadership, which SpaceX has in spades.",
                "category": "company",
                "datetime": 1782570000,
                "headline": "Alphabet Is Joining the Dow Jones Industrial Average. 3 Surprising Reasons Why SpaceX Could Be Next."
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 2,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.6,
            "source_article_count": 131,
            "discarded_article_count": 107
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 23.7,
        "grade": "良好",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 1.5,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 1.5,
            "vcp_reason": "跌縮量(近10日3日)；站上MA50；升放量(近10日2日)；Ready=N；Confirm=Y",
            "vcp_metrics": {
              "up_days": 5,
              "vol_ref": 2742600,
              "down_days": 4,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 2276040,
              "avg_vol_20": 2287660,
              "avg_vol_30": 2742600,
              "range_pct_10": 0.06769653612376333,
              "range_pct_20": 0.06769653612376333,
              "range_pct_30": 0.12060946178424815,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": false,
              "down_shrink_ok": true,
              "up_expand_days": 2,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.8298840516298402,
              "dist_to_20d_high": 0.008750438839250519,
              "down_shrink_days": 3,
              "breakout_level_20d": 379.41,
              "vcp_breakout_confirm": true,
              "contraction_ratio_10_30": 0.5612871090069373
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.8,
          "rsiKdjPoints": 4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0.8,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 1,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.8,
            "details": {
              "atrPct": 2.2495679464975717,
              "turnoverUsdM": 1590.999460288524,
              "liquidityPoints": 0.8,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.6,
          "stopLevels": {
            "symbol": "US.AMGN",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 359.1692,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 2,
              "macd_score": 3,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.6,
            "stop_loss_percent": 4.5,
            "take_profit_price": 402.7685,
            "target_multiplier": 2.2,
            "technical_strength": 2.15,
            "take_profit_percent": 7.1
          },
          "positionPoints": 1.8,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.5780808068176446,
          "stopLossPercent": 4.4991358929951435,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.AMGN",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 85.71,
    "atr": {
      "atr": 8.4604,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.25
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": 186.96
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "平衡",
      "score": 4,
      "value": 0.0441
    },
    "kdj": {
      "d": 60.03,
      "j": 90.07,
      "k": 70.04,
      "rule": "Cursor_18.24 K/D cross",
      "score": 6,
      "signal": "強金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "平衡",
      "score": 6,
      "value": 57.31
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": 12426269,
      "recentSlope": 1039956.9,
      "previousSlope": -741180
    },
    "rsi": 58.17,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 355.3119,
      "position": "SAR喺價下",
      "distancePct": 5.52,
      "previousTrend": "上升"
    },
    "ma50": 351.0186,
    "macd": {
      "macd": 5.755413887864336,
      "trend": "強烈看漲",
      "signal": 5.247816567951524,
      "histogram": 0.5075973199128114
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 366.5262,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 25
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.82,
      "score": 6,
      "avgVolume": 2318663,
      "currentVolume": 4230369
    },
    "derived": {
      "ma20": 365.9835,
      "ma50": 351.0186,
      "prevClose": 376.04,
      "avgVolume10": 2492607,
      "avgVolume20": 2318663,
      "changePercent": 0.01,
      "avgVolumeForScore": 2318663
    },
    "ma_cross": {
      "ma20": 365.9835,
      "ma50": 351.0186,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 365.0955,
      "prevMa50": 350.2258,
      "spreadPct": 4.26,
      "isVolumeBreakout": true
    },
    "bollinger": {
      "lower": 354.7865,
      "upper": 377.1805,
      "position": "上半部"
    },
    "rsi_short": 83.98,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.82
    }
  }
}

{
  "close": 376.09,
  "volume": 4230369,
  "changePercent": 0.01
}